TVI Colon 1
Alternative Names: TVI-Colon-1Latest Information Update: 28 Dec 2022
Price :
$50 *
At a glance
- Originator TVAX Biomedical
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (IV, Infusion)
- 14 Dec 2020 Preclinical trial is still ongoing in USA for Colorectal cancer (TVAX Biomedical website, December 2020)
- 14 Dec 2020 TVAX Biomedical has patent protection for its immunotherapy platform in the USA, Canada and in several European countries before December 2020 (TVAX Biomedical website, December 2020)